Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | AKT2 | P31751 | 5/20 | 0.33 |
| ▸ | AKT1 | P31749 | 2/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25741806 | 0.88 | KCNH2 (0.35) | KCNH2LMNAAPEX1PMP22NOS2 | |
| SCHEMBL26771785 | 0.85 | NR1I2 (0.36) | KCNH2LMNAAPEX1PMP22 | |
| SCHEMBL26775942 | 0.83 | KCNH2 (0.38) | KCNH2LMNAAPEX1PMP22NOS2 | |
| SCHEMBL7879844 | 0.80 | — | — | |
| SCHEMBL27708589 | 0.78 | — | — | |
| SCHEMBL569016 | 0.78 | — | — | |
| SCHEMBL3250415 | 0.78 | — | — | |
| SCHEMBL7992699 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL31273944 | 0.77 | LMNA (0.40) | KCNH2LMNAAPEX1PMP22NOS2 | |
| SCHEMBL23732512 | 0.77 | NR1I2 (0.36) | KCNH2LMNAAPEX1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| EP-4201426-A1 | PHARMACEUTICAL COMPOSITIONS FOR INDUCING HDAC7 EXPRESSION | Fundació Institut de Recerca Contra la Leucèmia Josep Carreras (ES) | 2023-06-28 | — | — | EP | disclosed |
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200055860-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC | 2020-02-20 | — | — | US | disclosed |
| US-20110183947-A1 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055860-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, ROR1 | KCNH2 3788/4885LMNA 2693/4885APEX1 3975/4885 |
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | KCNH2 348/4885LMNA 798/4885APEX1 2892/4885 |
| US-20110183947-A1 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | FAAH, FAAH2, FADS1 | KCNH2 194/4885LMNA 2491/4885APEX1 2553/4885 |
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | RET, BRAF, ROR1 | KCNH2 3779/4885LMNA 2727/4885APEX1 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.